Novo Nordisk shares drop after company reveals updated growth strategy

Shares in Danish pharmaceutical giant Novo Nordisk fell nearly five percent on Monday morning. The drop followed a growth strategy update at its capital markets day in London. The Copenhagen Post reported the market reaction to the new corporate plan.

Chief Executive Officer Mike Doustdar presented the updated strategy to investors. He said Novo will strengthen its core diabetes and weight-loss businesses. The company also plans to expand into liver and cardiovascular diseases. Novo aims to launch at least five major blockbuster medicines.

Novo Nordisk is Denmark's largest company and a major employer in Copenhagen. Its strategic updates closely influence job markets and business sentiment across Denmark.